NCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
24 trialsNCT04803318 2024-06-25
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06301386 2024-03-08
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
Fudan University
Phase 2 Not yet recruiting
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00729482 2020-01-07
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Asan Medical Center
Phase 2 Completed
NCT01648465 2019-09-03
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT01005199 2019-05-15
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00419159 2019-04-23
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Novartis
Phase 2 Completed
NCT02305810 2018-11-07
A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
European Institute of Oncology
Phase 2 Completed
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT01567488 2018-01-03
EVERLAR
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01379521 2017-05-03
TRACER
Novartis
Phase 2 Terminated
NCT00519324 2016-11-18
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
Novartis
Phase 2 Completed
NCT00390364 2014-10-08
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00409292 2014-08-11
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00632268 2013-08-21
Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
National Taiwan University Hospital
Phase 2 Completed
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed
NCT01423708 2012-07-18
EPOCAL
Azienda Ospedaliera di Padova
Phase 2 Unknown
NCT00775073 2012-04-30
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Treiber, Gerhard
Phase 2 Completed
NCT01387880 2012-03-20
ICE
Herlev Hospital
Phase 2 Completed
NCT01525719 2012-02-03
CRAD001T
Ratchavithi Hospital
Phase 2 Unknown
NCT00973713 2009-09-09
RADiChol
Austin Health
Phase 2 Unknown